Comparing of Neuralstem Inc. (CUR) and Allakos Inc. (NASDAQ:ALLK) – MS Wkly

Neuralstem Inc. (NASDAQ:CUR) and Allakos Inc. (NASDAQ:ALLK), both competing one another are Biotechnology companies. We will compare their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

Table 1 demonstrates Neuralstem Inc. and Allakos Inc.s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides Neuralstem Inc. and Allakos Inc.s net margins, return on equity and return on assets.

Liquidity

The Current Ratio of Neuralstem Inc. is 3.8 while its Quick Ratio stands at 3.8. The Current Ratio of rival Allakos Inc. is 20.5 and its Quick Ratio is has 20.5. Allakos Inc. is better equipped to clear short and long-term obligations than Neuralstem Inc.

Institutional & Insider Ownership

The shares of both Neuralstem Inc. and Allakos Inc. are owned by institutional investors at 4.9% and 97.4% respectively. Insiders held 1% of Neuralstem Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Neuralstem Inc. was more bearish than Allakos Inc.

Summary

Allakos Inc. beats Neuralstem Inc. on 7 of the 9 factors.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companys stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Visit link:
Comparing of Neuralstem Inc. (CUR) and Allakos Inc. (NASDAQ:ALLK) - MS Wkly